Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
AbstractPurpose of ReviewObesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the appl...
Source: Current Cardiology Reports - March 29, 2024 Category: Cardiology Source Type: research
GSE262398 Chemically induced expansion of type 2 alveolar epithelial cell promotes regenerative lower airway repair [RNA-seq]
Contributors : Sida Shao ; Nan Zhang ; Gregory P Specht ; Shaochen You ; Shuangwei Li ; Van Nguyen-Tran ; Sean B Joesph ; Arnab K Chatterjee ; Jeffrey J Chen ; Peter G Schultz ; Michael J BollongSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensType 2 alveolar epithelial cells (AEC2s) are stem cells in the adult lung that contribute to lower airway repair. Agents that promote the selective expansion of these cells might stimulate regeneration of the compromised alveolar epithelium, an etiology defining event in several pulmonary diseases. From a high content imaging screen of the d...
Source: GEO: Gene Expression Omnibus - March 27, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Expression of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in the rat submandibular gland is influenced by pre- and post-natal high-fat diet exposure
Conclusion: Exposure to HFD during pre- and post-natal periods increased GLP-1 mRNA expression in the SMGs of male rats. However, GIP expression decreased following the HFD in male newborns. Furthermore, a decreasing trend of GIP mRNA expression was observed in male newborns after HFD feeding. Sex influenced incretin hormones secretion and obesity-related conditions. HFD during pre- and post-natal periods reprograms the epigenome, contributing to subsequent disease development. (Source: Frontiers in Physiology)
Source: Frontiers in Physiology - March 26, 2024 Category: Physiology Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1
In conclusion, sotagliflozin was found to have an effect on GLP-1 and also stimulate the release of glucagon and FGF21, which are important for regulating fat metabolism. Therefore, sotagliflozin might represent a potential therapeutic approach for the treatment of diabetic dyslipidemia and steatohepatitis.PMID:38527859 | DOI:10.1111/1440-1681.13854 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - March 25, 2024 Category: Drugs & Pharmacology Authors: Nitin J Deshmukh M S Kalshetti Mohan Patil Pankaj Autade Ganesh V Sangle Source Type: research
